Biotech Values

[gophie]

Hereditary Angioedema is getting too crowded. Jerini AG has basically bowed out of the race. GENZ is smart enough to realize that DX-88 will not have first mover advantage for this rare disease (6,000 - 10,000 U.S. pts) and that C1-INH works effectively in 90% of the acute cases for the last 30 years in Europe. So don't be fooled by the spin from Dyax.

The first to cross the finish line will most likely be Lev Pharmaceuticals, Inc. (LEVP.OB)/Sanquin. They have a human C1-INH for Acute Hereditary Angioedema in Phase 3. They expect to file a BLA in 1Q07 (trial initiated in 1Q05). C1-INH is given by intravenous administration. Published studies by others have shown C1-INH treatment to resolve angioedema in 30 minutes to two hours.

Next in line may be Dyax.

And then there is ZLB Behring.

Pharming is just going through the motion pretending to be a player in HAE and trying to raise as much money as they can before LEV's human C1-INH hits the market.

Disclosure: No share ownership in any of these companies.